Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Prostatic Neoplasms 2Neoplasms 2Malnutrition 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Thrombosis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sexuality 1Sexual Dysfunction, Physiological 1Salivary Gland Neoplasms 1Radiation Injuries 1Protein Metabolism 1Polycystic Ovary Syndrome 1Pain 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Mucositis 1Meningioma 1Hemorrhage 1Glioblastoma 1Erectile Dysfunction 1Disease 1Diabetes Insipidus 1Brain Neoplasms 1

Interventions

lutetium Lu 177 dotatate 34Everolimus 33lanreotide 13gallium Ga 68 dotatate 13Temozolomide 13Magnetic Resonance Spectroscopy 13Nivolumab 12pembrolizumab 11Octreotide 11Capecitabine 11177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9surufatinib 8Sunitinib 8Specimen Handling 7Carboplatin 7pasireotide 6amino-acid, glucose, and electrolyte solution 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Lutetium-177 5Ipilimumab 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5Bevacizumab 5telotristat ethyl 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuroendocrine Tumors × Arginine × Clear all
NCT03478358 2022-08-31

Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Peking Union Medical College Hospital

Phase 1 Unknown
60 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡